Weekly Digest releases report on investment opportunities in connection with the H1N1 outbreak

Oct 21 2009

Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for GlaxoSmithKline (NYSE: GSK), Sanofi-Aventis (NYSE: SNY), Novartis (NYSE: NVS), Baxter International (NYSE: BAX), Roche Holding (OTC: RHHBY) and several others.

After posting large gains throughout 2009, swine flu stocks are seeing their largest pullback yet. For investors looking to position their portfolios for flu season, there are more ways to trade the flu than ever. Investors have large-cap pharmaceutical plays to choose from, and some of the more volatile, small-cap names have proven the efficacy of their drugs, while others are too far behind in their clinical trials to capitalize on the current pandemic.

To receive a free, 23-page report offering in depth analysis of the various participants in the vaccine and antiviral market, as well as some peripheral plays focusing directly on the impact of the current H1N1 swine flu pandemic, please visit the following link:

The report covers these topics and more:

• Which small- and large-cap swine flu plays have a real chance of benefiting in the event of a serious H1N1 outbreak, and which are riding on the hype?

• What sets Glaxo apart from its competitors when considering its ability to generate revenue from swine flu-related products?

• Can investors in drug giants like Novartis, Sanofi-Aventis and Roche expect these stocks to rise as a result of increased vaccine revenue?

• Baxter isn't supplying vaccine to the United States. How big is its global exposure, and is it among the large-cap pharmaceutical firms best positioned to address the swine flu threat?